Postoperative Antithrombotic Management After CABG with Bioprosthetic Mitral Valve Replacement

Early Anticoagulation (First 3 Months)

• Warfarin is reasonable for the first three months after bioprosthetic mitral valve replacement, targeting an INR of 2.0‑3.0 (≈2.5). – American College of Cardiology/American Heart Association (Class IIa, Level C) 1
• Early warfarin therapy mitigates the heightened risk of ischemic stroke that occurs during the first 90‑180 days while the prosthetic valve endothelializes. – American College of Cardiology (Class IIa) 3

Long‑Term Antithrombotic Strategy

Patients without additional thrombo‑embolic risk factors

• Transition to low‑dose aspirin (75‑100 mg daily) for lifelong therapy after the initial three‑month warfarin period. – American College of Cardiology/American Heart Association (Class I) 4

Patients with risk factors (atrial fibrillation, prior thrombo‑embolism, left‑ventricular dysfunction, hyper‑coagulable state)

• Continue warfarin indefinitely, maintaining an INR of 2.0‑3.0. – American College of Cardiology (Class I) 6
• Add low‑dose aspirin (75‑100 mg daily) to warfarin in these high‑risk patients. – American College of Cardiology (Class I) 6

Antiplatelet Therapy for Coronary Grafts

• Aspirin 75‑100 mg daily is mandatory for all CABG patients to preserve graft patency and should be continued lifelong unless contraindicated. – American College of Cardiology (Class I) 8
• When combined with warfarin for a bioprosthetic mitral valve, aspirin 75‑100 mg remains appropriate. – American College of Cardiology (Class I) 1

Lipid Management

• All CABG patients should receive statin therapy (unless contraindicated) with a target LDL < 100 mg/dL and at least a 30 % reduction from baseline. – American College of Cardiology (Class I) 8
• Statin therapy should never be discontinued peri‑operatively or post‑operatively. – American College of Cardiology (Class I) 8

Beta‑Blocker Therapy

• Beta‑blockers should be reinstated as soon as the patient is hemodynamically stable after CABG and continued at discharge in all eligible patients. – American College of Cardiology (Class I) 8
• Beta‑blocker use reduces postoperative atrial fibrillation and improves long‑term outcomes. – American College of Cardiology (Class I) 8

ACE‑Inhibitor/ARB Therapy

• ACE inhibitors or ARBs should be prescribed in patients with left‑ventricular dysfunction, diabetes, or hypertension. – American College of Cardiology (Class I) 8

Contraindication of Direct Oral Anticoagulants (DOACs)

• DOACs must not be used as alternatives to warfarin in patients with bioprosthetic mitral valves. – American College of Cardiology/American Heart Association (Class III: Harm) 1

Bleeding and Stroke Risk Considerations

• Warfarin increases bleeding risk (hazard ratio ≈ 1.32) but provides a modest survival benefit (hazard ratio ≈ 0.87); the benefit‑risk profile supports its use in the early postoperative period. – American College of Cardiology (Class IIa) 3
• INR should be monitored closely, especially during the first three months when anticoagulation is most critical. – American College of Cardiology (Class I) 1
• The highest stroke risk occurs within the first 30‑90 days after surgery; ischemic stroke incidence within 30 days is about 1.5 % despite routine anticoagulation. – American College of Cardiology (Class IIa) 3

Clinical Decision Algorithm (Key Steps)

Step 1 – Risk‑Factor Assessment

• Assess for atrial fibrillation, prior thrombo‑embolism, left‑ventricular dysfunction, or hyper‑coagulable state. – American College of Cardiology 4

Step 2 – No Risk Factors Present

• Start warfarin targeting INR 2.0‑3.0 for three months, then transition to lifelong low‑dose aspirin. – American College of Cardiology/American Heart Association 1

Step 3 – Risk Factors Present

• Continue warfarin indefinitely (INR 2.0‑3.0) and add low‑dose aspirin; maintain both medications long‑term. – American College of Cardiology 6

Step 4 – Universal Therapies (All Patients)

• Initiate statin therapy with LDL target < 100 mg/dL. – American College of Cardiology 8
• Re‑initiate beta‑blocker as soon as stable. – American College of Cardiology 8
• Prescribe ACE inhibitor or ARB when left‑ventricular dysfunction, diabetes, or hypertension is present. – American College of Cardiology 8